VANCOUVER, BC, October 6, 2021 / PRNewswire / – United States News Group – As vaccine passport programs continue to expand into new markets around the world, particularly in Europe and North America, it seems that the argument remains open, because
in many parts of the world, reluctance and rejection of vaccination persist. So while multiple injections have been cleared for emergency use in the period we are at now, there are still others who are working through different phases of testing with alternative forms of administration and technology, including BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Novavax, Inc. (NASDAQ: NVAX), Sanofi (NASDAQ: SNY), GlaxoSmithKline plc (NASDAQ: GSK) and Inovio Pharmaceuticals, Inc. (NASDAQ: INO).
By partnering with 63 billion dollars Chinese organic manufacturer WuXi organic products, BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) announced that it has moved closer to its COVID-19 vaccine candidate BVX-0320, which uses haptenized protein technology based on the work of the immunologist and Nobel Prize winner , Dr. Karl Landsteiner.
BVX-0320 works by initiating a T cell mediated immune response against SARS-CoV-2. T lymphocytes (or T lymphocytes, which are white blood cells essential in tumor rejection) react against the haptenized material, and T lymphocytes also react against the unmodified target protein.
In vivo studies have shown that BVX-0320, BioVaxysmonovalent haptenized s-spike protein vaccine, stimulated a 96.4% antibody response, activation of CD4 + helper T cells and CD8 + killer T cells, and stimulation of cytokine-producing T cells, gamma interferon.
The agreement with WuXi involves the biological manufacture of high synthesized yields of the fully characterized SARS-CoV-2 protein s for BioVaxys” Good Laboratory Practice (GLP) Safety Studies.
BioVaxys President and Chief Operating Officer Kenneth Kovan said: “The production of recombinant protein s using WuXi organic productsThe proprietary cell expression system is an important step in Biovaxis, because we not only have a high yield of protein production, but also maintain the ability and know-how to produce proteins on a large scale with the level of purity, consistency and protein characterization required by the FDA for our clinical and commercial studies. large-scale yields.
The company is currently in research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320.
BioVaxys continues to evaluate the development stages of a versatile version of BVX-0320 to treat new emerging variants of SARS-CoV-2 such as the highly transmissible virus UK (line B.1.1.7), South Africa (line B.1.351), and Brazil (lineage P.1) which are of major concern to governments around the world, healthcare professionals and infectious disease researchers.
Not too late for the party, Novavax, Inc. (NASDAQ: NVAX) is set to test its Covid-19 vaccine candidate in another trial in the UK. The study is designed to explore the heterologous regimen of Covid-19 vaccines from different manufacturers in adolescents 12 to 16 years old.
It will be critical to broaden our understanding of how different COVID-19 vaccines can be used to implement flexible immunization programs across all age groups to control the pandemic, ”said Gregory M. Glenn, MD , president of research and development, Novavax. “A mixed vaccination series could offer the potential to maximize the use of the existing vaccine supply, increase the total number of people who can ultimately be vaccinated, and accelerate rapid and equitable access across the world. “
The joint work of the French pharmaceutical giant is also catching up Sanofi (NASDAQ: SNY) and partners GlaxoSmithKline plc (NASDAQ: GSK), which is now in its Phase 3 trial.
Already, Spain has committed to purchase 500,000 doses of the new Sanofi-GSK Covid-19 vaccine, for which manufacturers hope to gain approval by the end of 2021. The total order from all EU member states is estimated at 72 million doses. The Sanofi-GSK offer is also a delivery of mRNA, just like those of Pfizer and Moderna.
Down South America, Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is heading to Brazil for its phase 3 Covid-19 vaccine trial, for its DNA vaccine candidate INO-4800.
So far, INO-4800 has a strong safety profile, and unlike other COVID-19 vaccine candidates, INO-4800 is administered intradermally and has caused only very severe side effects. limited (mainly mild reactions at the injection site).
“With many countries around the world experiencing low vaccination rates and increasing infections, we feel the urgency to advance INO-4800 globally,” said Dr. J. Joseph Kim, President and CEO of INOVIO. “I am incredibly proud of the INOVIO team and grateful to the health authorities of Brazil for their commitment to advance the fight against COVID-19. INOVIO the focus on supporting the global pandemic response is unwavering – and will highlight the potential benefits of INO-4800, which in addition to being well tolerated with balanced neutralizing antibodies and T cell responses (CD8 and CD4), has a strong thermostability profile, and potentially offers the potential to serve as both a primary vaccine and a booster vaccine. “
For more information, please visit: https://biotech-today.com/heres-why-you-want-biotech-stocks-in-your-portfolio/
Source of the article:
United States News group
DISCLAIMER: Nothing in this publication should be taken as personal financial advice. We are not permitted under securities laws to deal with your special financial situation. Any communication from our employees about you should not be considered personal financial advice. Please consult a licensed financial advisor before making any investment decisions. This is paid advertising and is not an offer or a recommendation to buy or sell any security. We do not hold any investment license and are therefore neither licensed nor qualified to provide investment advice. The contents of this report or e-mail are not provided to any person in view of their personal circumstances. United States News Group is a wholly owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ received advertising and digital media fees from BioVaxys Technology Corp. directly from the company. Third parties may own shares of BioVaxys Technology Corp. and liquidate their shares, which could have a negative effect on the share price. This compensation constitutes a conflict of interest with respect to our ability to remain objective in our communication concerning the profiled company. Due to this conflict, individuals are strongly encouraged not to use this publication as the basis for any investment decision. The owner / operator of MIQ owns shares of BioVaxys Technology Corp. which were purchased as part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of BioVaxys Technology Corp. at any time thereafter without further notice. We also expect further compensation as an ongoing digital media effort to increase the visibility of the company, no further notice will be given, but this disclaimer will serve as a notice that all material broadcast by MIQ has been approved by the company mentioned above; this is a paid advertisement, and we own shares of the company mentioned which we will sell, and we also reserve the right to buy shares of the company in the open market, or through others private placements and / or investment vehicles.
Although all information is believed to be reliable, we do not guarantee its accuracy. Individuals should assume that all information in our newsletter is not trustworthy unless verified by their own independent research. In addition, since events and circumstances often do not turn out as expected, there will likely be differences between forecasts and actual results. Always consult a licensed investment professional before making an investment decision. Be extremely careful, investing in securities carries a high degree of risk; you could probably lose some or all of your investment.
United States News Group is the source for all of the content listed above. FN Media Group, LLC (FNM), is a third-party publisher and information dissemination service provider, which distributes electronic information through multiple online media channels. FNM is NOT affiliated in any way with USA News Group or any company mentioned in this document. Comments, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not in any way reflect the views or opinions of FNM. The FNM is not responsible for the investment decisions of its readers or subscribers. FNM and its affiliates are a provider of information dissemination and financial marketing solutions and are NOT a registered broker / trader / analyst / advisor, do not hold any license to invest and may not sell, offer to sell or offer. to buy securities. FNM has not been remunerated by any public company mentioned in this document to distribute this press release.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made in accordance with to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results or strategies and are usually preceded by words such as “may”, “future”, ” plan “or” planned “,” will “or” should “,” expected “,” anticipate “,” draft “,” possibly “or” planned “. You are cautioned that these statements are subject to a multitude of risks and uncertainties which could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ. substantially from those projected. in forward-looking statements due to various factors and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other documents filed by that company with the Securities and Exchange Commission. You should take these factors into account when evaluating the forward-looking statements included in this document and not place undue reliance on such statements. The forward-looking statements contained in this press release are made as of the date hereof and FNM does not undertake to update such statements.
Media contact details:
FN Media Group, LLC
Media contact email address:
Phone in USA: +1(954)345-0611
THE SOURCE United States News group